The Tight Junction Protein ZO-1 Establishes a Link between the Transmembrane Protein Occludin and the Actin Cytoskeleton

Alan S. Fanning, Brian J. Jameson, Lynne Jesaitis, +1

Journal of Biological Chemistry

Protein SecretionMolecular BiologyTransmembrane Protein OccludinCytoskeletonCell Junctions +14

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu

Yu‐Tzu Tai, Myles Dillon, Weihua Song, +19

Blood

The Tight Junction Protein ZO-2 Contains Three PDZ (PSD-95Discs-LargeZO-1) Domains and an Alternatively Spliced Region

Martin D. Beatch, Lynne Jesaitis, Warren J. Gallin, +2

Journal of Biological Chemistry

2020 White Paper on Recent Issues in Bioanalysis: Vaccine Assay Validation, qPCR Assay Validation, QC for CAR-T Flow Cytometry, NAb Assay Harmonization and ELISpot Validation ( <u>Part 3</u> –Recommendations on Immunogenicity Assay Strategies, NAb Assays, Biosimilars and FDA/EMA Immunogenicity Guidance/Guideline, Gene &amp; Cell Therapy and Vaccine Assays)

Bart Corsaro, Tong‐Yuan Yang, Rocio Murphy, +51

Bioanalysis

Immunogenicity of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients With Morquio A Syndrome: Results From MOR-004, a Phase III Trial

Becky Schweighardt, Troy Tompkins, Kelly Lau, +7

Clinical Therapeutics

Elosulfase AlfaAutoimmune DiseaseAllergyEnzyme Replacement TherapyImmunodeficiencies +6

Pharmacokinetic and Pharmacodynamic Evaluation of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients with Morquio A Syndrome

Yulan Qi, Donald G. Musson, Becky Schweighardt, +4

Clinical Pharmacokinetics

Long-term Immunogenicity of Elosulfase Alfa in the Treatment of Morquio A Syndrome: Results From MOR-005, a Phase III Extension Study

Brian Long, Troy Tompkins, Celeste Decker, +6

Clinical Therapeutics

Safety, immunogenicity, and clinical outcomes in patients with Morquio A syndrome participating in 2 sequential open-label studies of elosulfase alfa enzyme replacement therapy (MOR-002/MOR-100), representing 5 years of treatment

Christian J. Hendriksz, Saikat Santra, Simon Jones, +6

Molecular Genetics and Metabolism

Antibodies that neutralize cellular uptake of elosulfase alfa are not associated with reduced efficacy or pharmacodynamic effect in individuals with Morquio A syndrome

Andrew C. Melton, Russell K. Soon, Troy Tompkins, +9

Journal of Immunological Methods

Immunocytochemical TechniqueImmunologyPathologyImmunophenotypingImmunotherapy +19

The <i>extended auricle1</i> (<i>eta1</i>) Gene Is Essential for the Genetic Network Controlling Postinitiation Maize Leaf Development

Karen S. Osmont, Lynne Jesaitis, Michael Freeling

Genetics